These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31101754)

  • 21. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
    Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
    Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticancer approach by targeted activation of a global inhibitor of sialyltransferases with acrolein.
    Kasahara T; Chang TC; Yoshioka H; Urano S; Egawa Y; Inoue M; Tahara T; Morimoto K; Pradipta AR; Tanaka K
    Chem Sci; 2024 Jun; 15(25):9566-9573. PubMed ID: 38939146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Selectins and Their Ligands in Cancer.
    Natoni A; Macauley MS; O'Dwyer ME
    Front Oncol; 2016; 6():93. PubMed ID: 27148485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth.
    Büll C; Boltje TJ; Wassink M; de Graaf AM; van Delft FL; den Brok MH; Adema GJ
    Mol Cancer Ther; 2013 Oct; 12(10):1935-46. PubMed ID: 23974695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of O-glycan sialylation in C6 cultured glioma cells: evidence for post-translational regulation of a beta-galactoside alpha 2,3 sialyltransferase activity by N-glycosylation.
    Broquet P; George P; Geoffroy J; Reboul P; Louisot P
    Biochem Biophys Res Commun; 1991 Aug; 178(3):1437-43. PubMed ID: 1872858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased alpha2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma.
    Pousset D; Piller V; Bureaud N; Monsigny M; Piller F
    Cancer Res; 1997 Oct; 57(19):4249-56. PubMed ID: 9331085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
    Podar K; Zimmerhackl A; Fulciniti M; Tonon G; Hainz U; Tai YT; Vallet S; Halama N; Jäger D; Olson DL; Sattler M; Chauhan D; Anderson KC
    Br J Haematol; 2011 Nov; 155(4):438-48. PubMed ID: 21923653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. System Xc
    Wang F; Oudaert I; Tu C; Maes A; Van der Vreken A; Vlummens P; De Bruyne E; De Veirman K; Wang Y; Fan R; Massie A; Vanderkerken K; Shang P; Menu E
    Cancer Lett; 2022 Jun; 535():215649. PubMed ID: 35315341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-Aza-2'-deoxycytidine increases sialyl Lewis X on MUC1 by stimulating β-galactoside:α2,3-sialyltransferase 6 gene.
    Chachadi VB; Cheng H; Klinkebiel D; Christman JK; Cheng PW
    Int J Biochem Cell Biol; 2011 Apr; 43(4):586-93. PubMed ID: 21168523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal Stromal Cells Regulate Sialylations of N-Glycans, Affecting Cell Migration and Survival.
    Templeton K; Ramos M; Rose J; Le B; Zhou Q; Cressman A; Ferreyra S; Lebrilla CB; Fierro FA
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deficiency of the sialyltransferase St3Gal4 reduces Ccl5-mediated myeloid cell recruitment and arrest: short communication.
    Döring Y; Noels H; Mandl M; Kramp B; Neideck C; Lievens D; Drechsler M; Megens RT; Tilstam PV; Langer M; Hartwig H; Theelen W; Marth JD; Sperandio M; Soehnlein O; Weber C
    Circ Res; 2014 Mar; 114(6):976-81. PubMed ID: 24425712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.
    Nair-Gupta P; Rudnick SI; Luistro L; Smith M; McDaid R; Li Y; Pillarisetti K; Joseph J; Heidrich B; Packman K; Attar R; Gaudet F
    Blood Cancer J; 2020 Jun; 10(6):65. PubMed ID: 32483120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib.
    Muz B; Azab F; de la Puente P; Rollins S; Alvarez R; Kawar Z; Azab AK
    Biomed Res Int; 2015; 2015():417586. PubMed ID: 26539491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
    Edwards CM; Lwin ST; Fowler JA; Oyajobi BO; Zhuang J; Bates AL; Mundy GR
    Am J Hematol; 2009 May; 84(5):268-72. PubMed ID: 19296472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.
    Braham MV; Deshantri AK; Minnema MC; Öner FC; Schiffelers RM; Fens MH; Alblas J
    Int J Nanomedicine; 2018; 13():8105-8118. PubMed ID: 30555229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
    Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
    Waldschmidt JM; Simon A; Wider D; Müller SJ; Follo M; Ihorst G; Decker S; Lorenz J; Chatterjee M; Azab AK; Duyster J; Wäsch R; Engelhardt M
    Br J Haematol; 2017 Oct; 179(1):36-49. PubMed ID: 28670693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.
    Jakubikova J; Cholujova D; Hideshima T; Gronesova P; Soltysova A; Harada T; Joo J; Kong SY; Szalat RE; Richardson PG; Munshi NC; Dorfman DM; Anderson KC
    Oncotarget; 2016 Nov; 7(47):77326-77341. PubMed ID: 27764795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.